MentalHealthDaily

Empagliflozin for Depression: Effective Adjunct with SSRIs (2024 Clinical Trial)

Major Depressive Disorder (MDD) impacts millions globally, making it a significant public health challenge. Traditional treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) don’t work for everyone, highlighting the need for innovative approaches. Recent clinical trials exploring the use of empagliflozin, a medication originally used to lower blood sugar in diabetes patients, have shown promising results …

Abnormal Brain EEG Activity Doesn’t Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression is a multifaceted mental health condition that presents significant challenges in both diagnosis and treatment. Recent studies have explored the potential of electroencephalography (EEG) as a predictive tool for treatment outcomes in major depressive disorder (MDD), with particular focus on the response to antidepressants like escitalopram. Highlights: EEG Abnormalities & Antidepressant Response: Contrary to …

Sex-Specific Biomarkers in Antidepressant Treatment for Depression: Male vs. Female (2023 Review)

by GLOOM

Depression, a complex and multifaceted disorder, presents differently in men and women, not only in symptoms but also in how each sex/gender responds to treatment. This divergence has led scientists to explore the molecular mechanisms behind these differences, revealing intricate biological and neurochemical pathways. Highlights: Sex-Specific Prevalence and Symptoms: Women are twice as likely as …

Lactofem Probiotic as Adjunct to SSRI Antidepressants May Enhance Mood & Sexual Satisfaction in Women (2024 Study)

by GLOOM

The link between mental health and sexual function is complex and multifaceted, with depressive disorders particularly affecting individuals’ sexual satisfaction and functionality. Recent research has highlighted the potential benefits of probiotics in mitigating these impacts, especially among women undergoing treatment with Selective Serotonin Reuptake Inhibitors (SSRIs). A new study conducted in Iran provides promising evidence …

Escitalopram (Lexapro) Normalizes Brain Connectivity in Major Depression (2024 Study)

by GLOOM

Major Depressive Disorder (MDD) significantly alters the brain’s network connectivity, with disturbances in the default mode network (DMN), salience network (SN), and dorsal attention network (DAN). A new study reveals how escitalopram, a common antidepressant, can partially reverse these abnormalities, offering insights into the biological underpinnings of its therapeutic effects. This research deepens our understanding …

SSRI-Induced Sexual Dysfunction Reversed with “Drug Holidays” on Weekends (2024 Study)

by GLOOM

Selective serotonin reuptake inhibitors (SSRIs) are a mainstay in the treatment of various mental disorders but often come with the unwelcome side effect of sexual dysfunction. This issue can significantly affect patients’ adherence to their medication regime, often leading to treatment discontinuation. A recent clinical trial offers a new perspective, suggesting that ‘drug holidays’ – …

Analyzing Serum Biomarkers to Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression, a complex and often debilitating mental health condition, affects millions globally. Despite advances in psychiatric medicine, finding the right treatment remains a challenge for many. A recent comprehensive study, however, is shedding light on this issue by examining the role of serum biomarkers in predicting the effectiveness of antidepressant therapy. Highlights: Innovative Approach: This …